BioSpace News Archive

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences

XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present a Company business update at the Wedbush PacGrow Virtual Healthcare Conference 2020.

Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Naïve Relapsed/Refractory Non-Hodgkin Lymphoma Patients

T2 Biosystems, Inc. announced that its Board of Directors has decided it will not seek authority from the stockholders at the 2020 Annual Meeting to effect a reverse split of its issued and outstanding shares of common stock and, accordingly, Proposal No. 1 in the Definitive Proxy Statement filed with the Securities and Exchange Commission on June 26, 2020 for such authority has been withdrawn from the agenda for the Annual Meeting.

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its P

Fujirebio Diagnostics Announces Initiation of Clinical Testing for the Fully Automated Lumipulse ® SARS CoV-2 Antigen Assay

White paper highlights potential of Heat’s vaccine to boost T cell immunity, alone or in combination with other vaccines

Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks; plan to initiate Phase 2 clinical trial under IND in 1H 2021 Reported positive top-line data for AXA1125, Axcella’s NASH product candidate, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation; plan to initiate Phase 2b clini

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 12, 2020, to review its financial results for the quarter ended June 30, 2020 and to provide a Company update.